Ivan Bergstein insider trades: Stemline Therapeutics (STML) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ivan reports to the SEC
Open-market buys and sales
23 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Apr 15, 2020 | STML | ↓ Sell | 53,618 | $4.88 | $262K | Direct | Apr 20, 2020 (5d) |
| Mar 10, 2020 | STML | ↓ Sell | 57,451 | $4.98 | $286K | Direct | Mar 13, 2020 (3d) |
| Feb 25, 2020 | STML | ↓ Sell | 24,642 | $6.42 | $158K | Direct | Feb 28, 2020 (3d) |
| Dec 27, 2019 | STML | ↓ Sell | 56,028 | $10.84 | $607K | Direct | Jan 3, 2020 (7d) |
| Aug 14, 2019 | STML | ↓ Sell | 35,010 | $14.73 | $516K | Direct | Aug 16, 2019 (2d) |
| Jun 26, 2019 | STML | ↓ Sell | 56,316 | $15.08 | $849K | Direct | Jun 28, 2019 (2d) |
| Mar 12, 2019 | STML | ↓ Sell | 57,224 | $11.11 | $636K | Direct | Mar 15, 2019 (3d) |
| Mar 7, 2019 | STML | ↓ Sell | 6,800 | $11.41 | $78K | Direct | Mar 8, 2019 (1d) |
| Feb 25, 2019 | STML | ↓ Sell | 22,905 | $12.03 | $276K | Direct | Feb 27, 2019 (2d) |
| Feb 14, 2019 | STML | ↓ Sell | 34,132 | $10.98 | $375K | Direct | Feb 15, 2019 (1d) |
| Mar 12, 2018 | STML | ↓ Sell | 37,857 | $17.34 | $656K | Direct | Mar 14, 2018 (2d) |
| Mar 7, 2018 | STML | ↓ Sell | 6,797 | $16.56 | $113K | Direct | Mar 9, 2018 (2d) |
| Feb 27, 2018 | STML | ↓ Sell | 24,183 | $17.42 | $421K | Direct | Feb 28, 2018 (1d) |
| Feb 15, 2018 | STML | ↓ Sell | 3,820 | $15.80 | $60K | Direct | Feb 16, 2018 (1d) |
| Mar 7, 2017 | STML | ↓ Sell | 5,401 | $8.13 | $44K | Direct | Mar 9, 2017 (2d) |
| Feb 28, 2017 | STML | ↓ Sell | 17,980 | $6.99 | $126K | Direct | Mar 1, 2017 (1d) |
| Feb 16, 2017 | STML | ↓ Sell | 3,652 | $6.42 | $23K | Direct | Feb 17, 2017 (1d) |
| Mar 8, 2016 | STML | ↓ Sell | 5,537 | $5.34 | $30K | Direct | Mar 10, 2016 (2d) |
| Feb 17, 2016 | STML | ↓ Sell | 3,244 | $4.46 | $14K | Direct | Feb 19, 2016 (2d) |
| Nov 30, 2015 | STML | ↓ Sell | 12,235 | $8.20 | $100K | Direct | Dec 1, 2015 (1d) |
| Feb 18, 2015 | STML | ↓ Sell | 3,180 | $14.02 | $45K | Direct | Feb 20, 2015 (2d) |
| Nov 26, 2014 | STML | ↓ Sell | 11,974 | $14.40 | $172K | Direct | Nov 26, 2014 (0d) |
| Sep 3, 2014 | STML | ↑ Buy | 2,000 | $11.05 | $22K | Direct | Sep 3, 2014 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Ivan Bergstein's insider trades
Ivan Bergstein is Chief Executive Officer at Stemline Therapeutics (STML). Since Sep 3, 2014, Ivan has reported 1 open-market purchase worth $22K and 22 sales worth $5.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (10 filings), shares returned to the company (1 filing), other transactions (1 filing), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every STML insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.